SBIR/STTR Research Award

High-Resolution Native Capillary Zone Electrophoresis with Inline UV and Native Mass Spectrometry for Characterizing Charge Variants in Biologics

Award identifier 3fd01bea156cf23c184d3448243a3efda664b9d7c1a955f37dc768c734e719a9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$350,000

Program and phase

SBIR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GMJ TECHNOLOGIES, INC.
Proposal award date
2024-08-01
Contract end date
2025-01-31
UEI
FLYLUW8AM585
Solicitation number
PA23-230
Topic code
400

Research abstract

PRJECT SUMMARY Fast evolution of blockbuster biologics such as monoclonal antibodies, antibody drug conjugates, fusion proteins, and gene therapy, is creating a strong demand for efficient analytical tools to characterize and monitor product variants that could negatively impact safety and efficacy. During production in cell culture, formulation, and storage, protein therapeutics can undergo post-translational modifications that could lead to charge variants (CVs). CVs are product variants with a net charge different from that of the intended product. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines identify CVs as a critical quality attribute because of their potential impact on the quality, safety, and efficacy of the product. Also, the U.S. Food and Drug Administration guidance recommends a comprehensive characterization of CVs in regulatory submissions. As a result, analytical monitoring of CVs is routine in product and process development, quality control and lot release. In the biopharmaceutical industry (biopharma), there is a growing interest in characterizing CVs with native mass spectrometry (MS) to ascertain the underlying post-translational modifications and potentially correlate with biological functions. For CVs characterization at the intact protein level, efficient separation is a critical step before MS detection to separate the variants, reduce sample complexity, and allow the detection of low abundant species. The most widely used separation techniques for CVs analysis in biopharma are (imaged) capillary isoelectric focusing and ion exchange chromatography but their applications for CVs characterization in native state are limited due to either inadequate resolution or incompatible separation conditions. GMJ Technologies (GMJ) is developing a high-resolution native capillary zone electrophoresis with native mass spectrometry for CVs characterization. Our approach combines multiple innovative solutions in capillary surface chemistry that produces high resolution of CVs by capillary zone electrophoresis, a novel optical-electrospray interface that provides inline optical and native mass detections, and a sensitive nanoflow electrospray mechanism that preserves proteins’ native conformation. With this innovation, GMJ aims to address a gap in the characterization and quality control of protein therapeutics from research to commercialization. By eliminating several laborious steps, the proposed technique will significantly improve the efficiency in the characterization workflow for CVs, improve the analysis precision and sensitivity, provide cost-saving benefits, and contribute to development and manufacturing of novel biologics and protein-based medicines.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2019–2025). Reported award amounts total $3,528,181. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.